Tetrabenazine for the treatment of tardive dyskinesia;Tetrabenazina para el tratamiento de discinesia tardía

Annals of Pharmacotherapy

Volumn 45, Issue 4, 2011, Pages 525-531

  Leung, Jonathan G ^a   Breden, Ericka L ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Movement disorders; Tardive dyskinesia; Tetrabenazine

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DIAZEPAM; HALOPERIDOL; METIROSINE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PLACEBO; TETRABENAZINE;

AKATHISIA; ANXIETY; ARTICLE; CHOREA; DEPRESSION; DROWSINESS; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; HUMAN; HYPERSALIVATION; INSOMNIA; MONOTHERAPY; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRIORITY JOURNAL; RESTLESSNESS; SEDATION; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; VOMITING; WEAKNESS;

ADRENERGIC UPTAKE INHIBITORS; CLINICAL TRIALS AS TOPIC; HUMANS; MOVEMENT DISORDERS; PROSPECTIVE STUDIES; TETRABENAZINE;

EID: 79955609673     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P312     Document Type: Article

References (38)

1. Miller CH, Fleischhacker W, Wolfgang W. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000;22:73-81.
2. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol 2007;27:59-69.
3. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21:151-6.
4. Hyde TM, Apud JA, Fisher WC, Egan MF. Tardive dyskinesia. In: Factor SA, Lang AE, eds. Drug-induced movement disorders. 2nd ed. Malden, MA: Blackwell Publishing, 2007:213-56.
5. Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J. Conventional vs newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999;7:70-6.
6. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;3:1209-23.
7. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H. Randomized controlled trial of the effect of quality of life of second-vs first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006;63: 1079-87.
8. Munetz MR, Benjamin S. How to examine patients using the abnormal involuntary movement scale. Hosp Community Psychiatry 1988;39:1172-7.
9. Haag H, Ruther E, Hippius H. Tardive dyskinesia. In: WHO expert series on biological psychiatry. Vol 1. Seattle, WA: Hogrefre and Huber Publishers. 1992.
10. De Keyser J. Excitotoxic mechanisms may be involved in the pathophysiology of tardive dyskinesia. Clin Neuropharmacol 1991;14:562-5.
11. Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev 2006 Jan 25;1:CD000459.
12. Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2006 Jul 19;3: CD000205.
13. Ogunmefun A, Hasnain M, Alam A, Osuala T, Regenold WT. Effect of donepezil on tardive dyskinesia. J Clin Psychopharmacol 2009;291:102-4.
14. Fahn S. Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents. Adv Neurol 1983;37:267-76.
15. Koch HJ, Szecsey A, Vogel M, Fisher-Barnicol D. Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride. Int J Clin Pract 2003;57:147-9.
16. Fasano A, Bentivoglio AR. Tetrabenazine. Expert Opin Pharmacother 2009;10:2883-96.
17. Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol 1982;12:257-62.
18. Product information. Xenazine (tetrabenazine). Deerfield, IL: Lundbeck Inc., September 2009.
19. Alentorn A, Palasi A, Campdelacreu J, Bruna J, Calopa M, Rubio F. Pelvic dyskinesia with an outstanding response to tetrabenazine. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:847-8.
20. Sharma H. Treatment of tardive dyskinesia by tetrabenazine, clonazepam and vitamin E. Indian J Psychiatry 2009;51:162-3.
21. Rauchverger B, Isakov V, Jabarin M. Olanzapine-induced tardive dystonia successfully treated by tetrabenazine. J Neuropsychiatry Clin Neurosci 2007;19:484-5.
22. Kalian M, Lerner V, Goldman M. Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine. J Nerv Ment Dis 1993;181:649-51.
23. Snell AP, Cleary M, Sambrook M. Treatment of tardive dyskinesia with choline and tetrabenazine. Postgrad Med J 1980;56:663-4.
24. Stevens E, Roman A, Houa M, Razavi D, Jaspar N. Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia. Intensive Care Med 1998;24:369-71.
25. Petzinger GM, Bressman SB. A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment. Mov Disord 1997;12: 246-8.
26. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 1972;27:95-9
27. Kazamatsuri H, Chien C-P, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 1973; 130:479-83.
28. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279-81.
29. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007; 22:193-7.
30. Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 2004; 27:230-3.
31. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-62.
32. Watson MW, Skelton D, Jamali F. Treatment of tardive dyskinesia: preliminary report on use of tetrabenazine. Can J Psychiatry 1988;33:11-3.
33. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38:391-4.
34. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982;11:41-7.
35. Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology 1981;31:1051-4.
36. Godwin-Austen RB, Clark T. Persistent phenothiazine dyskinesia treated with tetrabenazine. Br Med J 1971;4:25-6.
37. Product information. Reglan (metoclopramide). Marietta, GA: Alavenpharm, July 2009.
38. Caremark specialty trends Rx alert: Xenazine (tetrabenazine). https://www.caremark.com/portal/asset/SpecialtyTrendsRxAlert_Xenazine2.p df (accessed 2010 May 19).